Am. J. Respir. Cell Mol. Biol., Volume 25, Number 1, July, 2001 104-110

Endogenously Released Endothelin-1 from Human Pulmonary Artery Smooth Muscle Promotes Cellular Proliferation
Relevance to Pathogenesis of Pulmonary Hypertension and Vascular Remodeling

Stephen J. Wort, Mandy Woods, Timothy D. Warner, Timothy W. Evans, and Jane A. Mitchell

Adult Intensive Care Unit, Royal Brompton Hospital, Imperial College School of Medicine; and Department of Vascular Inflammation, William Harvey Research Institute, St. Bartholemews and the Royal London School of Medicine and Dentistry, London, United Kingdom

Endothelin (ET)-1 is a potent vasoconstrictor and comitogen/ proliferation factor for vascular smooth muscle (VSM). As such, it has been implicated in the vascular wall remodeling observed in pulmonary hypertension (PH). Although the endothelium is considered the main source of ET-1, it can be released by other cells including VSM and may mediate proliferation in an autocrine manner. We investigated this possibility using human pulmonary artery smooth-muscle (HPASM) cells. Serum stimulated the release of ET-1 from HPASM cells in a concentration-dependent fashion and caused proliferation as determined by [³H]thymidine uptake and increase in cell number. Addition of an ET-A receptor antagonist (BQ123) or an inhibitor of ET-1 synthesis (phosphoramidon) reduced the proliferation induced by serum, confirming an autocrine role for ET-1. In addition, treatment of HPASM cells with two drug types used in the management of PHcicaprost, a stable prostacyclin-mimetic; or diltiazem, a calcium-channel blockerreduced ET-1 release from these cells. We conclude that ET-1 released from HPASM cells has an autocrine function in serum-induced proliferation, with important implications for the pathogenesis of human vascular remodeling. Drugs used in the treatment of PH may act, at least in part, by inhibiting this autocrine loop.

This article has been cited by other articles:

				B. Tang, Y. Li, C. Nagaraj, R. E. Morty, S. Gabor, E. Stacher, R. Voswinckel, N. Weissmann, K. Leithner, H. Olschewski, et al. Endothelin-1 Inhibits Background Two-Pore Domain Channel TASK-1 in Primary Human Pulmonary Artery Smooth Muscle Cells Am. J. Respir. Cell Mol. Biol., October 1, 2009; 41(4): 476 - 483. [Abstract] [Full Text] [PDF]

				S. J. Wort, M. Ito, P.-C. Chou, S. K. Mc Master, R. Badiger, E. Jazrawi, P. de Souza, T. W. Evans, J. A. Mitchell, L. Pinhu, et al. Synergistic Induction of Endothelin-1 by Tumor Necrosis Factor {alpha} and Interferon {gamma} Is due to Enhanced NF-{kappa}B Binding and Histone Acetylation at Specific {kappa}B Sites J. Biol. Chem., September 4, 2009; 284(36): 24297 - 24305. [Abstract] [Full Text] [PDF]

				I. P. Laumanns, L. Fink, J. Wilhelm, J.-C. Wolff, R. Mitnacht-Kraus, S. Graef-Hoechst, M. M. Stein, R. M. Bohle, W. Klepetko, M. A. R. Hoda, et al. The Noncanonical WNT Pathway Is Operative in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 683 - 691. [Abstract] [Full Text] [PDF]

				S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart, March 1, 2007; 93(3): 350 - 354. [Abstract] [Full Text] [PDF]

				H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies Cardiovasc Res, October 1, 2006; 72(1): 30 - 40. [Abstract] [Full Text] [PDF]

				D. Langleben, J. Dupuis, I. Langleben, A. M. Hirsch, M. Baron, J.-L. Senecal, and M. Giovinazzo Etiology-Specific Endothelin-1 Clearance in Human Precapillary Pulmonary Hypertension Chest, March 1, 2006; 129(3): 689 - 695. [Abstract] [Full Text] [PDF]

				S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease Heart, November 1, 2005; 91(11): 1447 - 1452. [Abstract] [Full Text] [PDF]

				N. Kunichika, J. W. Landsberg, Y. Yu, H. Kunichika, P. A. Thistlethwaite, L. J. Rubin, and J. X.-J. Yuan Bosentan Inhibits Transient Receptor Potential Channel Expression in Pulmonary Vascular Myocytes Am. J. Respir. Crit. Care Med., November 15, 2004; 170(10): 1101 - 1107. [Abstract] [Full Text] [PDF]

				J. L. Wright, H. Tai, and A. Churg Cigarette Smoke Induces Persisting Increases of Vasoactive Mediators in Pulmonary Arteries Am. J. Respir. Cell Mol. Biol., November 1, 2004; 31(5): 501 - 509. [Abstract] [Full Text] [PDF]

				E.D. Moloney and T.W. Evans Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome Eur. Respir. J., April 1, 2003; 21(4): 720 - 727. [Abstract] [Full Text] [PDF]

				S. J. Smith, S. Brookes-Fazakerley, L. E. Donnelly, P. J. Barnes, M. S. Barnette, and M. A. Giembycz Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L279 - L289. [Abstract] [Full Text] [PDF]

				S. J. Wort, M. Woods, T. D. Warner, T. W. Evans, and J. A. Mitchell Cyclooxygenase-2 Acts as an Endogenous Brake on Endothelin-1 Release by Human Pulmonary Artery Smooth Muscle Cells: Implications for Pulmonary Hypertension Mol. Pharmacol., November 1, 2002; 62(5): 1147 - 1153. [Abstract] [Full Text] [PDF]

				R. P. Jankov, R. Belcastro, E. Ovcina, J. Lee, H. Massaeli, S. J. Lye, and A. K. Tanswell Thromboxane A2 Receptors Mediate Pulmonary Hypertension in 60% Oxygen-exposed Newborn Rats by a Cyclooxygenase-independent Mechanism Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 208 - 214. [Abstract] [Full Text] [PDF]

				T W Evans, M A Gatzoulis, and J S R Gibbs A National Pulmonary Hypertension Service for England & Wales: an orphan disease is adopted? Thorax, June 1, 2002; 57(6): 471 - 472. [Full Text] [PDF]